South Africa

Country Background
South Africa remains one of the worst affected countries by the HIV/AIDS epidemic. The HIV/AIDS prevalence in South Africa is 21.5% among adults and 29% among expectant mothers.   It is estimated that there are 222,000 infants born each year to HIV positive mothers. The funding and infrastructure are not evenly distributed in South Africa. The HIV/AIDS testing is more accessible in some provinces such as Western Cape and Kwazulu-Natal, while some other provinces such as Eastern and Northern Cape face greater challenges in accessing to reagents and supplies for HIV/AIDS testing.

  GHI in South Africa

GHI in South Africa
In 2008, a group of Kellogg graduates met with key thought leaders in HIV/AIDS programs, in South Africa and Mozambique, and also visited a number of healthcare facilities involved in early infant diagnosis of HIV.  The team conducted Point of Care Cost-Benefit Analysis to better understand the key costs and benefits issues of the current infant HIV/AIDS diagnosis system. The national market size for infant tests was estimated and unmet market needs were determined.  Product concepts were tested, and key attributes such as accuracy, mobility and efficiency were evaluated by the local health care providers.

GHI future work in South Africa
Additional research needs to be done by GHI to better understand the immediate needs and infrastructure limitations of the provinces with weaker funding and infrastructure. The costs and benefits will be further evaluated to determine the appropriate infant diagnosis model for different provinces. GHI will continue to identify and develop potential partnerships for infant diagnosis in South Africa.